Promacta and Aplastic anemia - a phase IV clinical study of FDA data

Summary:

Aplastic anemia is found among people who take Promacta, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Promacta and have Aplastic anemia. It is created by eHealthMe based on reports of 14,537 people who have side effects when taking Promacta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 18, 2023

14,537 people reported to have side effects when taking Promacta.
Among them, 57 people (0.39%) have Aplastic anemia.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 14,571 Promacta users for its effectiveness, alternative drugs and more.

What is Aplastic anemia?

Aplastic anemia is found to be associated with 1,358 drugs and 827 conditions by eHealthMe.

Number of Promacta and Aplastic anemia reports submitted per year:

Time on Promacta when people have Aplastic anemia *:

Gender of people who have Aplastic anemia when taking Promacta *:

female: 50.91 %
male: 49.09 %

Age of people who have Aplastic anemia when taking Promacta *:

Common drugs people take besides Promacta *:

Common side effects people have besides Aplastic anemia *:

Thrombocytopenia (decrease of platelets in blood): 17 people, 29.82%
Drug Ineffective: 11 people, 19.30%
Fever: 8 people, 14.04%
Fatigue (feeling of tiredness): 8 people, 14.04%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 8.77%
White Blood Cell Count Decreased: 5 people, 8.77%
Weakness: 5 people, 8.77%
Nausea (feeling of having an urge to vomit): 4 people, 7.02%
Disease Progression: 4 people, 7.02%
Anaemia (lack of blood): 4 people, 7.02%

Common conditions people have *:

Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 11 people, 19.30%
Thrombocytopenia (decrease of platelets in blood): 5 people, 8.77%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 5 people, 8.77%
Spinal Compression Fracture (fracture due to spinal compression on bone): 4 people, 7.02%
Osteoporosis (bones weak and more likely to break): 4 people, 7.02%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 5.26%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 3 people, 5.26%
Neoplasm Malignant (cancer tumour): 2 people, 3.51%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 1.75%
Iron Overload: 1 person, 1.75%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and have Aplastic anemia?

Check whether Aplastic anemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Aplastic anemia and when was it recovered:

Aplastic anemia in Promacta

Expand to all the drugs that have ingredients of eltrombopag olamine:

Aplastic anemia and drugs with ingredients of eltrombopag olamine (72 reports)

Alternative drugs to, pros and cons of Promacta:

Promacta (14,571 reports)

Common Promacta side effects:

Death: 2,356 reports
Thrombocytopenia (decrease of platelets in blood): 2,268 reports
Drug ineffective: 1,190 reports
Fatigue (feeling of tiredness): 745 reports
Headache (pain in head): 573 reports
Diarrhea: 493 reports

Browse all side effects of Promacta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Aplastic anemia treatments and more:

Aplastic anemia (12,996 reports)

COVID vaccines that are related to Aplastic anemia:

Common drugs associated with Aplastic anemia:

All the drugs that are associated with Aplastic anemia:

Aplastic anemia (1,358 drugs)

Common conditions associated with Aplastic anemia:

High blood pressure: 254 reports
Rheumatoid arthritis: 200 reports
Epilepsy: 138 reports
Hepatitis c: 103 reports

All the conditions that are associated with Aplastic anemia:

Aplastic anemia (827 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eltrombopag olamine (the active ingredients of Promacta) and Promacta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.